PepGen, Inc. (NASDAQ:PEPG) Receives $11.75 Consensus PT from Analysts

by · The Cerbat Gem

Shares of PepGen, Inc. (NASDAQ:PEPG – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $11.75.

A number of research analysts have issued reports on PEPG shares. HC Wainwright increased their target price on shares of PepGen from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen upgraded PepGen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Stifel Nicolaus raised their price objective on PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Guggenheim reaffirmed a “buy” rating and issued a $6.00 price objective on shares of PepGen in a report on Wednesday, September 24th. Finally, Wedbush increased their target price on PepGen from $7.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, September 25th.

Get Our Latest Research Report on PepGen

PepGen Price Performance

PEPG stock opened at $6.67 on Friday. PepGen has a fifty-two week low of $0.88 and a fifty-two week high of $7.80. The stock has a market capitalization of $458.56 million, a price-to-earnings ratio of -2.37 and a beta of 1.91. The business’s fifty day moving average price is $5.44 and its two-hundred day moving average price is $3.37.

PepGen (NASDAQ:PEPG – Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.11. Research analysts expect that PepGen will post -2.73 EPS for the current year.

Hedge Funds Weigh In On PepGen

Hedge funds have recently bought and sold shares of the company. Nuveen LLC bought a new stake in shares of PepGen during the 1st quarter worth approximately $139,000. Adage Capital Partners GP L.L.C. boosted its holdings in shares of PepGen by 68.8% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,350,000 shares of the company’s stock valued at $1,897,000 after purchasing an additional 550,000 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of PepGen in the 1st quarter valued at $122,000. Woodline Partners LP bought a new position in shares of PepGen in the 1st quarter valued at $1,097,000. Finally, Marshall Wace LLP acquired a new position in shares of PepGen during the 2nd quarter worth $44,000. 58.01% of the stock is owned by institutional investors.

PepGen Company Profile

(Get Free Report)

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).

See Also